文献速递血栓与止血

前瞻性血友病抑制物PUP研究揭示FVIII抑制物清除期间独特的抗体特征

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.
PubMed 文献 · Blood Adv · 2023-01-01

血友病抑制物PUP研究(HIPS)是一项前瞻性临床试验,5例产生持续性FVIII抑制物的重型血友病A患者进入ITI延伸臂(HIPS-ITI),接受同一FVIII产品ITI,每月采集血样并分析FVIII结合抗体特征。ITI成功或部分成功2例、失败3例;成功组FVIII抑制物消失,伴高亲和力FVIII特异性抗体(尤其IgG1和IgG4亚类)清除或滴度持续最小化;失败组表现为抑制物持续,伴高亲和力FVIII特异性抗体持续存在。

要点

  • ITI成功2例、部分成功2例、失败3例,成功需FVIII抑制物消失。
  • 成功组伴高亲和力FVIII特异性抗体(尤其IgG1和IgG4亚类)清除或滴度持续最小化。
  • 失败组以抑制物持续为特征,伴高亲和力FVIII特异性抗体持续存在。

核心结论

  • ITI成功需要FVIII抑制物消失,这与高亲和力FVIII特异性抗体(尤其IgG1和IgG4亚类)的清除或滴度持续最小化相关;ITI失败表现为FVIII抑制物持续,伴高亲和力FVIII特异性抗体持续存在。

研究设计与样本

  • HIPS为前瞻性临床试验,纳入重型血友病A的既往未治疗患者(PUP),观察免疫系统变化。
  • 5例在HIPS期间产生持续性FVIII抑制物的患者进入ITI延伸臂(HIPS-ITI)。
  • HIPS-ITI中患者接受同一FVIII产品(单一来源的重组人全长FVIII)进行ITI,直至成功耐受、宣告失败或HIPS-ITI入组后最多2年,以先发生者为准。
  • 每月采集血样和临床数据,在每个采样时间点测定纵向FVIII结合抗体特征、相关结合特异性及表观亲和力。

主要发现

  • ITI成功或部分成功2例,失败3例。
  • 两组呈现不同的FVIII特异性抗体特征。
  • ITI成功需FVIII抑制物消失,伴高亲和力FVIII特异性抗体(尤其IgG1和IgG4亚类)清除或滴度持续最小化。
  • ITI失败表现为FVIII抑制物持续,伴高亲和力FVIII特异性抗体持续存在。
  • 1例部分ITI成功和1例ITI失败患者在ITI期间出现明显的寡反应性FVIII结合抗体,其真实性质需未来研究更全面随访。

局限性

  • 1例部分ITI成功和1例ITI失败患者出现的寡反应性FVIII结合抗体的真实性质需要未来研究更全面的随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Factor VIII (FVIII) inhibitor formation is a major clinical concern during replacement therapy in patients with hemophilia A. Immune tolerance induction (ITI) is the only therapeutic approach to attempt inhibitor eradication and establishment of long-term immune tolerance to FVIII. Hemophilia Inhibitor Previously Untreated Patient (PUP) Study (HIPS) was a prospective clinical trial to investigate changes in the immune system of PUPs with severe hemophilia A. Five patients who developed persistent FVIII inhibitors during HIPS entered an ITI extension arm (HIPS-ITI). During HIPS-ITI, inhibitor patients received ITI with the same FVIII product (a single source of recombinant, human full-length FVIII) used in HIPS until successful tolerance, declared failure, or a maximum of 2 years after HIPS-ITI enrollment, whichever came first. Blood samples and clinical data were collected monthly. Longitudinal FVIII-binding antibody signatures, associated binding specificities, and apparent affinities were determined for each patient at each sampling time point. ITI was successful or partially successful in 2 patients and failed in 3. Both groups presented with distinct FVIII-specific antibody signatures. ITI success required the disappearance of FVIII inhibitors, which was associated with the eradication or sustained titer minimization of high-affinity FVIII-specific antibodies, particularly of the immunoglobulin G1 (IgG1) and IgG4 subclasses. In contrast, ITI failure, as reflected by FVIII inhibitor persistence, was associated with persistent high-affinity FVIII-specific antibodies. Interestingly, 1 patient with partial ITI success and 1 patient with ITI failure developed apparent oligoreactive FVIII-binding antibodies during ITI. The explanation of the true nature of these antibodies requires more comprehensive follow-ups in future studies. This trial was registered at www.clinicaltrials.gov as #NCT01652027.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Paul H, Berg V, Gangadharan B, et al. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication. Blood Adv. 2023. PMID: 36074992. doi:10.1182/bloodadvances.2022007267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。